The presence or rise of established or novel MM subclones with single or double TP53 deficiencies could thus be detected and the information potentially be used for therapeutic decisions as well as for retrospective analyses that promote our understanding of the precise genetic features that underlie the unfavourable clinical courses of MM with TP53 lesions. The gene discussed is TP53; the disease is Miyoshi myopathy.